NCCN guidelines recommend intensified chemotherapy with or without ASCT consolidation for r/r ALCL, however, this is not an effective treatment for all ALK+ALCL.<h4>Case report</h4>Herein, we report a patient with relapsed/refractory ALK+ ALCL who received crizotinib and brentuximab vedotin as bridging therapy, followed by autologous stem cell transplantation and sequential anti-CD30 CAR T cell therapy.<h4>Conclusion</h4>The patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.